Beximco Pharmaceuticals Limited (AIM:BXP)
London flag London · Delayed Price · Currency is GBP · Price in GBX
38.00
+0.50 (1.33%)
Apr 17, 2025, 4:35 PM GMT+1

Beximco Pharmaceuticals Ratios and Metrics

Millions GBP. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Apr '25 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2015 - 2019
Market Capitalization
263355473607675267
Upgrade
Market Cap Growth
-47.94%-24.94%-22.18%-10.03%152.96%-15.35%
Upgrade
Enterprise Value
308420574741745369
Upgrade
Last Close Price
0.380.370.320.600.720.27
Upgrade
PE Ratio
6.219.0414.1413.4615.437.99
Upgrade
PS Ratio
0.851.191.661.992.681.10
Upgrade
PB Ratio
0.741.011.371.552.120.86
Upgrade
P/TBV Ratio
0.891.241.701.962.250.92
Upgrade
P/FCF Ratio
-8.2717.7528.7522.588.51
Upgrade
P/OCF Ratio
-6.3010.7213.2313.135.06
Upgrade
EV/Sales Ratio
1.071.402.022.432.961.52
Upgrade
EV/EBITDA Ratio
4.696.258.8410.2011.705.98
Upgrade
EV/EBIT Ratio
5.657.5211.4812.7813.757.22
Upgrade
EV/FCF Ratio
11.289.7821.5735.0624.9211.76
Upgrade
Debt / Equity Ratio
0.120.120.220.280.200.32
Upgrade
Debt / EBITDA Ratio
0.580.601.181.501.021.62
Upgrade
Debt / FCF Ratio
1.510.952.895.162.183.18
Upgrade
Asset Turnover
0.640.640.580.590.580.52
Upgrade
Inventory Turnover
1.771.871.771.912.031.91
Upgrade
Quick Ratio
0.600.520.370.350.390.35
Upgrade
Current Ratio
2.132.181.571.451.471.15
Upgrade
Return on Equity (ROE)
12.45%11.79%9.81%12.19%14.72%11.31%
Upgrade
Return on Assets (ROA)
7.62%7.48%6.38%6.95%7.75%6.76%
Upgrade
Return on Capital (ROIC)
9.45%8.92%7.49%8.06%8.98%7.75%
Upgrade
Return on Capital Employed (ROCE)
14.10%13.90%12.30%12.30%14.80%13.90%
Upgrade
Earnings Yield
1611.46%11.06%7.07%7.43%6.48%12.52%
Upgrade
FCF Yield
1038.57%12.09%5.63%3.48%4.43%11.76%
Upgrade
Dividend Yield
5.46%7.36%8.04%5.11%4.15%4.86%
Upgrade
Payout Ratio
2496.42%27.21%33.98%31.68%11.28%17.13%
Upgrade
Total Shareholder Return
5.46%7.36%8.04%5.11%4.15%4.86%
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.